ADC Therapeutics SA - Common Shares (ADCT)

Historical Holders from Q2 2020 to Q3 2025

Symbol
ADCT on NYSE
Type / Class
Equity / Common Shares
Shares outstanding
124,058,172
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
68,158,412
Holdings value
$272,625,712
% of all portfolios
0.001%
Number of holders
105
Number of buys
53
Number of sells
-26
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADC Therapeutics SA - Common Shares (ADCT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 14% $41,986,839 15,666,731 Redmile Group, LLC 30 Jun 2025
HPWH TH AG 9.61% $14,291,858 9,788,944 Dr. Hans-Peter Wild 15 May 2025
Point72 Asset Management, L.P. 7% $21,693,047 7,831,425 Point72 Asset Management, L.P. 16 Jun 2025
Prosight Management, LP 5.8% $28,781,496 7,195,374 Prosight Management, LP 30 Sep 2025
BlackRock, Inc. 5% -4% $7,173,203 -$144,108 4,913,153 -2% BlackRock, Inc. 31 Mar 2025
Oaktree Capital Group Holdings GP, LLC 4.14% $18,693,764 4,673,441 Oaktree Fund Administration, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 3.6% $5,019,207 3,437,813 ORBIMED CAPITAL LLC 31 Dec 2024

Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 68,158,412 $272,625,712 -$9,526,921 $4 105
2025 Q2 67,952,003 $182,114,158 +$35,606,077 $2.68 84
2025 Q1 54,846,167 $77,332,587 -$2,528,133 $1.41 82
2024 Q4 56,494,277 $112,422,732 -$3,041,138 $1.99 82
2024 Q3 54,883,537 $172,881,709 +$3,394,419 $3.15 76
2024 Q2 51,801,951 $163,693,841 +$51,364,315 $3.16 73
2024 Q1 34,683,534 $155,728,721 +$7,168,355 $4.49 36
2023 Q4 33,953,461 $56,361,695 -$3,915,509 $1.66 36
2023 Q3 39,458,503 $35,390,528 -$10,272,333 $0.897 40
2023 Q2 45,357,348 $97,515,460 -$1,939,928 $2.15 55
2023 Q1 46,611,135 $90,890,151 +$6,156,453 $1.95 57
2022 Q4 38,834,584 $149,117,927 +$3,712,534 $3.84 59
2022 Q3 36,621,247 $176,523,672 +$9,038,590 $4.82 60
2022 Q2 34,475,113 $274,062,429 +$4,571,679 $7.95 52
2022 Q1 34,123,674 $501,279,862 +$2,970,760 $14.69 44
2021 Q4 33,799,357 $682,750,000 +$19,180,842 $20.2 50
2021 Q3 32,792,604 $890,647,136 -$45,594,727 $27.16 51
2021 Q2 33,533,099 $816,251,800 +$17,173,667 $24.35 53
2021 Q1 32,826,058 $801,283,858 +$19,636,706 $24.41 55
2020 Q4 32,141,073 $1,028,835,000 +$31,200,598 $32.01 51
2020 Q3 28,226,306 $921,776,783 +$216,837,760 $32.99 51
2020 Q2 21,557,623 $1,000,339,109 +$1,000,339,111 $46.81 41